According to Fierce Biotech, ARPA-H has launched a new autism research initiative called SPECTRA. The program is meant to address gaps in how autism spectrum disorder is studied and treated, though the source does not provide details on the program's funding or timeline.
Researchers involved in SPECTRA will work on an end-to-end system that identifies ASD risk factors, links patients to suitable interventions, and accelerates clinical research for new therapies. The goal appears to be a more integrated approach from early detection through treatment development.
Since this article draws on a single source, there are no differing accounts to compare. The reported scope of SPECTRA is broad, but the source offers limited specifics beyond the program's stated aims.